Safety and Efficacy of Dabigatran, Apixaban and Rivaroxaban Versus Warfarin in Treatment-Naive Frail Patients with Nonvalvular Atrial Fibrillation
Phase of Trial: Phase IV
Latest Information Update: 24 May 2018
Price : $35 *
At a glance
- Drugs Apixaban (Primary) ; Dabigatran etexilate (Primary) ; Rivaroxaban (Primary) ; Warfarin
- Indications Embolism; Stroke
- Focus Adverse reactions; Therapeutic Use
- 24 May 2018 According to a Janssen Pharmaceuticals media release, results from this study were also published the Journal of the American Heart Association.
- 24 May 2018 Results presented in a Janssen Pharmaceuticals media release.
- 08 May 2018 New trial record